Modeling the cytochrome P450-mediated metabolism of chlorinated volatile organic compounds

Drug Metabolism and Disposition

Volumn 24, Issue 2, 1996, Pages 203-210

  Waller, Chris L ^a,b   Evans, Marina V ^a   Mckinney, James D ^a  

^a Pharmacokinetics Branch   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; ORGANOCHLORINE DERIVATIVE; VOLATILE ORGANIC COMPOUND;

ARTICLE; ELECTRIC FIELD; METABOLIC RATE; MOLECULAR MODEL; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

CYTOCHROME P-450 ENZYME SYSTEM; ELECTROCHEMISTRY; HYDROCARBONS, CHLORINATED; ISOENZYMES; KINETICS; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP; VOLATILIZATION;

EID: 0030056293     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. D. R. Koop: Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB J 6, 724-730 (1992).
2. L. R. Pohl, B. Bhooshan, N. F. Whittaker, and G. Krishna: Phosgene: a metabolite of chloroform. Biochem. Biophys. Res. Comm. 79, 684-691 (1977).
3. F. P. Guengerich, D. H. Kim, and M. Iwasaki: Role of human cytochrome IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 4, 168-179 (1991).
4. J. L. Raucy, J. C. Kraner, and J. M. Lasker: Bioactivation of halogenated hydrocarbons by cytochrome P4502E1. Crit. Rev. Toxicol. 23, 1-20 (1993).
5. T. L. MacDonald: Chemical mechanisms of halocarbon metabolism. CRC Crit. Rev. Toxicol. 11, 85-120 (1983).
6. M. V. Anders, L. Lash, W. Dekant, A. A. Elferra, and D. R. Dohn: Biosynthesis and biotransformation of glutathione S-conjugates to toxic metabolites. CRC Crit. Rev. Toxicol. 18, 311-341 (1988).
7. H. W. Leung: Development and utilization of physiologically based pharmacokinetic models for toxicological applications. J. Toxicol. Environ. Health 32, 247-267 (1991).
8. M. L. Gargas, M. E. Andersen, and I. H. J. Clewell: A physiologically based simulation approach for determining metabolic constants from gas uptake data. Toxicol. Appl. Pharmacol. 86, 341-352 (1986).
9. J. Mordenti and W. Chappell: The use of interspecies scaling in toxicokinetics. In "Toxicokinetics and New Drug Development" (A. Yacobi, J. Skelly, and V. Batra, eds.), pp. 42-96. Pergamon Press, New York, 1989.
10. H. J. Clewell and M. E. Andersen: Risk assessment extrapolations and physiological modeling. Toxicol. Ind. Health 1, 111-131 (1985).
11. M. E. Andersen, D. Krewski, and J. R. Withey: Physiological pharmacokinetics and cancer risk assessment. Cancer Lett. 6, 1-14 (1993).
12. M. V. Evans, W. D. Crank, H. M. Yang, and J. E. Simmons: Applications of sensitivity analysis to a physiologically based pharmacokinetic model for carbon tetrachloride in rats. Toxicol. Appl. Pharmacol. 128, 36-44 (1994).
13. R. A. Corley, A. L. Mendrala, F. A. Smith, D. A. Staats, M. L. Gargas, R. B. Conolly, M. E. Andersen, and R. H. Retiz: Development of a physiologically based pharmacokinetic model for chloroform. Toxicol. Appl. Pharmacol. 103, 512-527 (1990).
14. M. E. Andersen, H. J. Clewell, M. L. Gargas, F. A. Smith, and R. H. Reitz: Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol. Appl. Pharmacol. 87, 185-205 (1987).
15. M. L. Gargas, P. G. Seybold, and M. E. Andersen: Modeling the tissue solubilities and metabolic rate constant (Vmax) of halogenated methanes, ethanes, and ethylenes. Toxicol. Lett. 43, 235-256 (1988).
16. G. A. Csanady, R. J. Laib, and J. G. Filser: Metabolic transformation of halogenated and other alkanes - a theoretical approach. Estimation of metabolic reactivities for in vivo conditions. Toxicol. Lett. 75, 217-223 (1995).
17. R. D. Cramer III, D. E. Patterson, and J. D. Bunce: Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am Chem. Soc. 110, 5959-5967 (1988).
18. S. M. Greene and G. R. Marshall: 3D-QSAR: A Current Perspective. Trends in Pharm. Sci. 16, 285-291 (1995).
19. T. I. Oprea, C. L. Waller, and G. R. Marshall: 3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results. Drug Des. Dis. 12, 29-51 (1994).
20. C. L. Waller and G. Marshall: Three-dimensional quantitative structure-activity relationship of angiotesin-converting enzyme and thermolysin inhibitors. II. A comparison of CoMFA models incorporating molecular orbital fields and desolvation free energies based on active-analog and complementary-receptor field alignment rules. J. Med. Chem. 36, 2390-2403 (1993).
21. J. B. Houston: Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47, 1469-1479 (1994).
22. M. L. Gargas, H. J. Clewell, and M. E. Andersen: Gas uptake inhalation techniques and the rates of metabolism of chloromethanes, chloroethanes, and chloroethylenes in the rat. Inhal. Toxicol. 2, 295-319 (1990).
23. M. Clark, I. Cramer, D. Richard, and N. Van Opdenbosch: Validation of the general purpose tripos 5.2 force field. J. Comput. Chem. 10, 982-1012 (1989).
24. M. V. Evans and M E. Andersen: Sensitivity analysis and the design of gas uptake inhalation studies. Inhal. Toxicol. in press.
25. A. Leo, C. Hansch, and D. Elkins: Partition coefficients and their uses. Chem. Rev. 71, 525-616 (1971).
26. G. E. Kellogg, S. F. Semus, and D. J. Abraham: HINT: a new method of empirical hydrophobic field calculation for CoMFA. J. Comput. Aided Mol. Des. 5, 545-552 (1991).
27. S. Wold, A. Ruhe, H. Wold, and W. J. Dunn: The covariance problem in linear regression. The partial least squares (PLS) approach to generalized inverses. SLAM J. Sci. Stat. Comp. 5, 735-743 (1984).
28. R. D. Cramer, J. D. Bunce, D. E. Patterson, and I. E. Frank: Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant. Struct.-Act. Relat. 7, 18-25 (1988).
29. K. Oguri and H. Yamada: Regiochemistry of cytochrome P450 isozymes. Ann. Rev. Pharmacol. Toxicol. 34, 251-279 (1994).
30. A. Tomasi, E. Albano, F. Biasi, T. F. Slater, V. Vannini, and M. U. Diaazani: Activation of chloroform and related trihalomethanes to free radical intermediates in isolated hepatocytes and in the rat in vivo as detected by the ESR-spin trapping technique. Chem.-Biol. Interact. 55, 303-316 (1985).
31. W. Nastainczyk, V. Ullrich, and H. Sies: Effect of oxygen concentration on the reaction of halothane with cytochrome P450 in liver microsomes and isolated perfused rat liver. Biochem. Pharmacol. 27, 387-392 (1978).
32. E. Testai, S. DiMarzio, and L. Vittozzi: Multiple activation of chloroform in hepatic microsomes from uninduced B6C3F1 mice. Toxicol. Appl. Pharmacol. 104, 496-503 (1990).
33. 3 carcinogenicity. Toxicol. Appl. Pharmacol. 114, 197-203 (1992).
34. C. L. Waller and J. D. McKinney: Theoretical investigation into the potential of halogenated methanes to undergo reductive metabolism. J. Comput. Chem. 14, 1575-1579 (1993).
35. B. T. Luke, G. H. Loew, and A. D. McLean: Theortical investigations of the anaerobic reduction of halogenated alkanes by cytochrome P-450. 1. Structures, inversion barriers, and heats of formation of halomethyl radicals. J. Am. Chem. Soc. 109, 1307-1317 (1987).
36. B. T. Luke and G. H. Loew: A theoretical investigation of the first step in the metabolic reduction of halogenated methanes by cytochrome P-450. Int. J. Quant. Chem. 12, 99-112 (1986).
37. B. T. Luke, G. H. Loew, and A. D. McLean: Theoretical investigation of the anaerobic reduction of halogenated alkanes by cytochrome P-450. 2. Vertical electron affinities of chlorofluoromethanes as a measure of their activity. J. Am. Chem. Soc. 110, 3396-3400 (1988).
38. V. DeCurtis, S. Gemma, M. Sbraccia, E. Testai, and L. Vittozzi: The contribution of electrophilic and radicalic intermediates to phospholipid adduces formed by halomethanes in vivo. J. Biochem. Toxicol. 9, 305-310 (1994).
39. R. Gebhardt: Metabolic zonation of the liver: regulation and implications for liver function. Pharmacol. Ther. 53, 275-354 (1992).
40. 2 uptake in periportal and pericentral regions of liver lobule: stop-flow experiments with perfused liver. J. Physiol. 244, G656-G659 (1983).
41. e test. Carcinogenesis 8, 253-264 (1987).